Indium (111In) biciromab

Indium (111In) biciromab
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category	N/A
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status	Withdrawn
CAS Number	138783-13-8
PubChem
DrugBank
ChemSpider	none
KEGG	D03111

Indium (¹¹¹In) biciromab (INN, trade name FibriScint, developed by Centocor) was a drug targeting fibrin, a protein involved in the clotting of blood.<ref>King, David J.,

 Recombinant antibodies for the diagnosis and therapy of human disease, 
 Current Opinion in Drug Discovery & Development, 
 1999,
 Vol. 2(Issue: 2),</ref> It was the Fab' fragment of a mouse monoclonal antibody labelled with the radioisotope indium-111 for the diagnosis of thromboembolism,<ref>Answers.com: Centocor Ortho Biotech Products, L.P.</ref> but was withdrawn during clinical trials.<ref>DiagnosticImaging.com: Centocor withdraws imaging agent applications</ref>

References

   This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!

   This article is a medical stub. You can help WikiMD by expanding it!